BIIB

#393
Biogen Inc. Common Stock
191.82
+2.91%
Sector:
Base:
Profit Currency:
Daily Range
191.82
191.82
Year Range
110.03
202.41
Daily Change
+2.91%
Monthly Change
+10.48%
6 month change
+40.67%
Year Change
+35.68%
Previous Close
186.39
Open
191.82
Bid
Ask
Low
191.82
High
191.82
Volume
256
Open full chart

Financials

Overview Statement Statistics Dividends
Quarterly Annual
  • Market Capitalization 28.1 B
  • Employee 7 500
  • Founded 1978
  • CEO Chris Viehbacher
  • Website www.biogen.com
  • Headquarter Delaware, United States
  • FIGI BBG000C17X76
  • Industry Technology
Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
20.02
Price to sales ratio
2.62
Dividends per share
—
Dividend yield %
—

Biogen Inc

Biogen Inc. is an American multinational biotechnology company based in Cambridge, Massachusetts, United States specializing in the treatment of neurological diseases. The company's primary products are dimethyl fumarate, diroximel fumarate, interferon beta-1a, peginterferon beta-1a, and natalizumab, all for the treatment of multiple sclerosis; nusinersen for the treatment of spinal muscular atrophy; omaveloxolone for the treatment of Friedreich's ataxia; tofersen for the treatment of ALS; and dimethyl fumarate for the treatment of severe plaque psoriasis. The company also produces 5 biosimilars and has collaborations with Genentech for several drugs. The company is ranked 424th on the Fortune 500 and 845th on the Forbes Global 2000.

News